Skip to main content
SpringerLink
Log in

Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders

Results of a 2-year extension study

  • ORIGINAL CONTRIBUTION
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to assess the longterm efficacy, safety, and tolerability of risperidone, over a cumulative period of 3 years, in treating children with disruptive behaviour disorders and below average intelligence (IQ 35–84).

Method

This trial included 35 children (aged 6–16 years), diagnosed with disruptive behaviour disorder. All subjects had previously completed a 1-year, open-label risperidone study, and this extension study followed them for an additional 2 years of treatment. Safety was assessed using the Extrapyramidal Symptom Rating Scale (ESRS), clinical laboratory tests, electrocardiograms, and the recording of adverse events, vital signs, Tanner score, and changes in body mass index (BMI). Efficacy was measured using the Clinical Global Impression of Severity (CGI-S) scale.

Results

The beneficial effects observed in the original trial were maintained during the extension. Few extrapyramidal side-effects occurred, as assessed by the ESRS, and there were no cases of tardive dyskinesia. The children showed a modest increase in BMI, part of which may be attributed to normal growth over the 2-year period. Most adverse events were mild or moderate in severity, and none of them were considered probably or very likely related to risperidone.

Conclusion

Continuing low-dose risperidone for up to 3 years appears to be safe and effective in children with disruptive behaviour disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aman MG, Tassé MJ, Rojahn J, Hammer D (1996) The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabilities 17:41–57

    CAS  Google Scholar 

  2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002) Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337–1346

    Article  PubMed  Google Scholar 

  3. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington DC

  4. Angold A, Costello EJ, Erkani A (1999) Comorbidity. J Child Psychol Psychiatry 40:57–87

    Article  CAS  PubMed  Google Scholar 

  5. Angold A, Erkanli A, Farmer EM, Fairbank JA, Burns BJ, Keeler G, Costello EJ (2002) Psychiatric disorder, impairment, and service use in rural African American and white youth. Arch Gen Psychiatry 59:893–901

    PubMed  Google Scholar 

  6. Bardone AM, Moffitt TE, Caspi A, Dickson N, Stanton WR, Silva PA (1998) Adult physical health outcomes of adolescent girls with conduct disorder, depression, and anxiety. J Am Acad Child Adolesc Psychiatry 37:594–601

    CAS  PubMed  Google Scholar 

  7. Buitelaar JK, van der Gaag, Cohen-Kettenis P, Melman CT (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239–248

    CAS  PubMed  Google Scholar 

  8. Chouinard G, Ross-Canard A, Annable L, Jones BD (1980) The Extrapyramidal Symptoms Rating Scale. Can J Neurol Sci 8:233

    Google Scholar 

  9. Croonenberghs J, Fegert JM, Findling RL, de Smedt G, Van Dongen S (2005) Risperidone in children with disruptive behavior disorders: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 44:64–72

    PubMed  Google Scholar 

  10. Dosen A (1993) Diagnosis and treatment of behavioral disorders in mentally retarded individuals: the state of the art. J Intellect Disabil Res 37(Suppl):1–7

    PubMed  Google Scholar 

  11. Dunbar F, Kusumakar V, Daneman D, Schulz M (2004) Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161:918–920

    Article  PubMed  Google Scholar 

  12. Emerson E (2003) Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Disabil Res 47:51–58

    CAS  PubMed  Google Scholar 

  13. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509–516

    CAS  PubMed  Google Scholar 

  14. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B; Risperidone Disruptive Behavior Study Group (2004) Long-term open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677–684

    Article  PubMed  Google Scholar 

  15. Gillberg C, Persson E, Grufman N, Themner U (1986) Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. Br J Psychiatry 149:68–74

    CAS  PubMed  Google Scholar 

  16. Hechtman L, Offord DR (1994) Long-term outcome of disruptive disorders. Child and Adolescent Psychiatry Clinics of North America 3:379–403

    Google Scholar 

  17. Kim EY, Miklowitz DJ (2002) Childhood mania, attention deficit hyperactivity disorder and conduct disorder: a critical review of diagnostic dilemmas. Bipolar Disord 4:215–225

    Article  PubMed  Google Scholar 

  18. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14:11–28

    Article  CAS  PubMed  Google Scholar 

  19. Lewis R (1998) Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 43:596–604

    CAS  PubMed  Google Scholar 

  20. Makra L, Juhasz M, Borsos E, Beczi R (2004) Meteorological variables connected with airborne ragweed pollen in Southern Hungary. Int J Biometeorol 49:37–47

    Article  CAS  PubMed  Google Scholar 

  21. Moss HB, Lynch KG (2001) Comorbid disruptive behavior disorder symptoms and their relationship to adolescent alcohol use disorders. Drug Alcohol Depend 64:75–83

    CAS  PubMed  Google Scholar 

  22. Pappadopulos E, MacIntyre JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS (2003) Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42:145–161

    PubMed  Google Scholar 

  23. Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, Baron-Myak C, McBurnett K (2000) Behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol 28:507–525

    CAS  PubMed  Google Scholar 

  24. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry, in press

  25. Rothenberg ME (1998) Eosinophilia. N Engl J Med 338:1592–600

    Article  CAS  PubMed  Google Scholar 

  26. Satterfield JH, Schell A (1997) A prospective study of hyperactive boys with conduct problems and normal boys: adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry 36:1726–1735

    CAS  PubMed  Google Scholar 

  27. Scott S, Knapp M, Henderson J, Maughan B (2001) Financial cost of social exclusion: follow up study of antisocial children into adulthood. BMJ 323 (7306):191–193

    CAS  PubMed  Google Scholar 

  28. Shrier LA, Harris SK, Kurland M, Knight JR (2003) Substance use problems and associated psychiatric symptoms among adolescents in primary care. Paediatrics 111(6 pt 1):e669–e705

    Google Scholar 

  29. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropscyhopharmacology 29:133–145

    CAS  Google Scholar 

  30. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A; Risperidone Conduct Study Group (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026–1036

    PubMed  Google Scholar 

  31. Soltys SM, Kashani JH, Dandoy AC, Vaidya AF, Reid JC (1992) Comorbidity for disruptive disorders in psychiatrically hospitalized children. Child Psychiatry Hum Dev 23:87–98

    Article  CAS  PubMed  Google Scholar 

  32. Sparrow S, Cicchetti D (1985) Diagnostic uses of the Vineland Adaptive Behavior Scales. J Ped Psychol 10:215–225

    CAS  Google Scholar 

  33. Stigler KA, Potenza MN, McDougle CJ (2001) Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3:927–942

    CAS  PubMed  Google Scholar 

  34. Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34

    Article  PubMed  Google Scholar 

  35. van Bellinghen M, de Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5–13

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton-Harbourton Road, Titusville (NJ) 08530, USA

    Magali Reyes MD, PhD

  2. Kenezy Gyula Hospital Child and Adolescent Psychiatry, Debrecen, Hungary

    Roza Olah MD

  3. Janssen-Cilag A Johnson and Johnson Company, Törökbálint, Tó Park, Hungary

    Krisztina Csaba MD

  4. Johnson and Johnson Research and Development LLC, Beerse, Belgium

    Ilse Augustyns PhD & Marielle Eerdekens MD

Authors
  1. Magali Reyes MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roza Olah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krisztina Csaba MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilse Augustyns PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marielle Eerdekens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reyes, M., Olah, R., Csaba, K. et al. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Eur Child Adolesc Psychiatry 15, 97–104 (2006). https://doi.org/10.1007/s00787-006-0504-0

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-006-0504-0

Key words

Search

Navigation